FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1034808906> ?p ?o ?g. }

• W1034808906 endingPage "172" @default.
• W1034808906 startingPage "1" @default.
• W1034808906 abstract "Background Ureteric colic, the term used to describe the pain felt when a stone passes down the ureter from the kidney to the bladder, is a frequent reason for people to seek emergency health care. Treatment with the muscle-relaxant drugs tamsulosin hydrochloride (Petyme, TEVA UK Ltd) and nifedipine (Coracten ® , UCB Pharma Ltd) as medical expulsive therapy (MET) is increasingly being used to improve the likelihood of spontaneous stone passage and lessen the need for interventional procedures. However, there remains considerable uncertainty around the effectiveness of these drugs for routine use. Objectives To determine whether or not treatment with either tamsulosin 400 µg or nifedipine 30 mg for up to 4 weeks increases the rate of spontaneous stone passage for people with ureteric colic compared with placebo, and whether or not it is cost-effective for the UK NHS. Design A pragmatic, randomised controlled trial comparing two active drugs, tamsulosin and nifedipine, against placebo. Participants, clinicians and trial staff were blinded to treatment allocation. A cost–utility analysis was performed using data gathered during trial participation. Setting Urology departments in 24 UK NHS hospitals. Participants Adults aged between 18 and 65 years admitted as an emergency with a single ureteric stone measuring ≤ 10 mm, localised by computerised tomography, who were able to take trial medications and complete trial procedures. Interventions Eligible participants were randomised 1 : 1 : 1 to take tamsulosin 400 µg, nifedipine 30 mg or placebo once daily for up to 4 weeks to make the following comparisons: tamsulosin or nifedipine (MET) versus placebo and tamsulosin versus nifedipine. Main outcome measures The primary effectiveness outcome was the proportion of participants who spontaneously passed their stone. This was defined as the lack of need for active intervention for ureteric stones at up to 4 weeks after randomisation. This was determined from 4- and 12-week case-report forms completed by research staff, and from the 4-week participant self-reported questionnaire. The primary economic outcome was the incremental cost per quality-adjusted life-year (QALY) gained over 12 weeks. We estimated costs from NHS sources and calculated QALYs from participant completion of the European Quality of Life-5 Dimensions health status questionnaire 3-level response (EQ-5D-3L™) at baseline, 4 weeks and 12 weeks. Results Primary outcome analysis included 97% of the 1167 participants randomised (378/391 tamsulosin, 379/387 nifedipine and 379/399 placebo participants). The proportion of participants who spontaneously passed their stone did not differ between MET and placebo [odds ratio (OR) 1.04, 95% confidence interval (CI) 0.77 to 1.43; absolute difference 0.8%, 95% CI –4.1% to 5.7%] or between tamsulosin and nifedipine [OR 1.06, 95% CI 0.74 to 1.53; absolute difference 1%, 95% CI –4.6% to 6.6%]. There was no evidence of a difference in QALYs gained or in cost between the trial groups, which means that the use of MET would be very unlikely to be considered cost-effective. These findings were unchanged by extensive sensitivity analyses around predictors of stone passage, including sex, stone size and stone location. Conclusions Tamsulosin and nifedipine did not increase the likelihood of stone passage over 4 weeks for people with ureteric colic, and use of these drugs is very unlikely to be cost-effective for the NHS. Further work is required to investigate the phenomenon of large, high-quality trials showing smaller effect size than meta-analysis of several small, lower-quality studies. Trial registration Current Controlled Trials ISRCTN69423238. European Clinical Trials Database (EudraCT) number 2010–019469–26. Funding This project was funded by the National Institute for Health Research Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 19, No. 63. See the NIHR Journals Library website for further project information." @default.
• W1034808906 created "2016-06-24" @default.
• W1034808906 creator A5000562097 @default.
• W1034808906 creator A5004165162 @default.
• W1034808906 creator A5008452829 @default.
• W1034808906 creator A5009243643 @default.
• W1034808906 creator A5012288512 @default.
• W1034808906 creator A5016923960 @default.
• W1034808906 creator A5018209581 @default.
• W1034808906 creator A5018595176 @default.
• W1034808906 creator A5027585011 @default.
• W1034808906 creator A5032979528 @default.
• W1034808906 creator A5056938637 @default.
• W1034808906 creator A5061749118 @default.
• W1034808906 creator A5062193556 @default.
• W1034808906 creator A5067772235 @default.
• W1034808906 creator A5070474989 @default.
• W1034808906 creator A5071650224 @default.
• W1034808906 creator A5075666079 @default.
• W1034808906 creator A5084883597 @default.
• W1034808906 creator A5087773005 @default.
• W1034808906 date "2015-08-01" @default.
• W1034808906 modified "2023-10-14" @default.
• W1034808906 title "Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tamsulosin) (the SUSPEND trial)" @default.
• W1034808906 cites W1101221 @default.
• W1034808906 cites W1527170510 @default.
• W1034808906 cites W1566155680 @default.
• W1034808906 cites W1621068964 @default.
• W1034808906 cites W1785898356 @default.
• W1034808906 cites W1875022435 @default.
• W1034808906 cites W1896232313 @default.
• W1034808906 cites W1957144217 @default.
• W1034808906 cites W1967199121 @default.
• W1034808906 cites W1969469734 @default.
• W1034808906 cites W1971531878 @default.
• W1034808906 cites W1972105537 @default.
• W1034808906 cites W1975396412 @default.
• W1034808906 cites W1977163919 @default.
• W1034808906 cites W1981450059 @default.
• W1034808906 cites W1983722797 @default.
• W1034808906 cites W1985918793 @default.
• W1034808906 cites W1990131018 @default.
• W1034808906 cites W1992201970 @default.
• W1034808906 cites W2002064046 @default.
• W1034808906 cites W2014318701 @default.
• W1034808906 cites W2020533282 @default.
• W1034808906 cites W2032174947 @default.
• W1034808906 cites W2034693214 @default.
• W1034808906 cites W2034698532 @default.
• W1034808906 cites W2038211365 @default.
• W1034808906 cites W2041143758 @default.
• W1034808906 cites W2046492941 @default.
• W1034808906 cites W2049532218 @default.
• W1034808906 cites W2052380200 @default.
• W1034808906 cites W2055065362 @default.
• W1034808906 cites W2057144863 @default.
• W1034808906 cites W2057354586 @default.
• W1034808906 cites W2061410297 @default.
• W1034808906 cites W2064300468 @default.
• W1034808906 cites W2064720974 @default.
• W1034808906 cites W2092052931 @default.
• W1034808906 cites W2093255760 @default.
• W1034808906 cites W2101778674 @default.
• W1034808906 cites W2104336232 @default.
• W1034808906 cites W2106225623 @default.
• W1034808906 cites W2106963789 @default.
• W1034808906 cites W2108233388 @default.
• W1034808906 cites W2111323078 @default.
• W1034808906 cites W2111515114 @default.
• W1034808906 cites W2123520542 @default.
• W1034808906 cites W2127824228 @default.
• W1034808906 cites W2132633916 @default.
• W1034808906 cites W2136369323 @default.
• W1034808906 cites W2148296514 @default.
• W1034808906 cites W2150248961 @default.
• W1034808906 cites W2150955784 @default.
• W1034808906 cites W2151061868 @default.
• W1034808906 cites W2163742315 @default.
• W1034808906 cites W2165502691 @default.
• W1034808906 cites W2328451703 @default.
• W1034808906 cites W2404160726 @default.
• W1034808906 cites W2434179590 @default.
• W1034808906 cites W2473786944 @default.
• W1034808906 cites W2950448456 @default.
• W1034808906 cites W4236805817 @default.
• W1034808906 cites W4292806894 @default.
• W1034808906 doi "https://doi.org/10.3310/hta19630" @default.
• W1034808906 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4781616" @default.
• W1034808906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26244520" @default.
• W1034808906 hasPublicationYear "2015" @default.
• W1034808906 type Work @default.
• W1034808906 sameAs 1034808906 @default.
• W1034808906 citedByCount "26" @default.
• W1034808906 countsByYear W10348089062016 @default.
• W1034808906 countsByYear W10348089062017 @default.
• W1034808906 countsByYear W10348089062018 @default.
• W1034808906 countsByYear W10348089062019 @default.
• W1034808906 countsByYear W10348089062021 @default.

• next